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Introduction {#sec005}
============

Since gonadotropin-releasing hormone agonist (GnRH-a) was developed in the 1980s \[[@pone.0175985.ref001]\], it has played an important role in controlled ovarian hyperstimulation (COH) among patients who are undergoing assisted reproductive technology (ART). The advantage of GnRH agonist is to prevent premature luteinizing hormone (LH) surge, thereby increasing the number of retrieved oocytes and pregnancy rates and decreasing the number of cycle cancellations \[[@pone.0175985.ref002], [@pone.0175985.ref003]\]. These advantages, however, may lead to ovarian hyperstimulation syndrome (OHSS) or other side effects \[[@pone.0175985.ref004]\].

GnRH antagonist (GnRH-ant), which was discovered in the 1990s, can competitively block GnRH receptors and cause rapid suppression of Gn release \[[@pone.0175985.ref005]\]. This protocol has fewer complications and is more convenient for patients because of the shorter treatment time and fewer injections \[[@pone.0175985.ref006]\]. However, its effectiveness is still debated.

Multiple studies, including meta-analyses and randomized controlled trials (RCTs), of the GnRH-a protocol and GnRH-ant protocol on pregnancy rate and live birth rate have yielded controversial findings \[[@pone.0175985.ref006]--[@pone.0175985.ref008]\]. A 2006 Cochrane systematic review of 27 RCTs showed that GnRH-ant protocol has a significantly lower clinical pregnancy rate and live birth rates than those in GnRH-a long protocol, while the incidence of OHSS is significantly lower in GnRH-ant protocol \[[@pone.0175985.ref009]\]. However, a 2011 Cochrane systematic review of 45 RCTs found that there was no significant difference in the live birth rates between the GnRH-a and GnRH-ant groups \[[@pone.0175985.ref010]\]. A recent Cochrane systematic review of 73 RCTs in 2016 also concluded that these two protocols have equivalent live birth rates, and GnRH-ant protocol has a lower incidence of OHSS \[[@pone.0175985.ref011]\].

The finding that GnRH-ant protocol reduces the pregnancy rate may result from the fact that some centers only choose GnRH-ant protocol as their second treatment option in COH, or use it to treat the patients with an unfavorable prognosis, such as repeated implantation failures, older patients, and low responders \[[@pone.0175985.ref012]\]. This study's purpose is to determine the effectiveness and safety of GnRH-a long protocol and GnRH-ant protocol among patients with normal ovarian reserve to unify the influencing factors.

Materials and methods {#sec006}
=====================

Search strategy {#sec007}
---------------

"GnRH agonist", "GnRHa", "GnRH antagonist", "GnRH-ant", "GnRHA", "randomized controlled trial", "RCT", and "Normal ovarian reserve" were used as the keywords for the literature searches in the PubMed (1992--2016), Cochrane Library (1999--2016), Web of Science (1950--2016), Chinese Biomedical Database (CBM,1979--2016), and China National Knowledge Infrastructure (CNKI,1994--2016) databases. The retrieval time was from the first publication of the journal to the end of December 2016. References included in the studies were also searched.

Inclusion and exclusion criteria {#sec008}
--------------------------------

Inclusion criteria were RCTs that compared the effectiveness and safety of GnRH-a long protocol and GnRH-ant protocol in patients with normal ovarian reserve. Exclusion criteria included failure to report appropriate randomized procedures, classification of participants as low or high ovarian response or endometriosis, and unclear or inappropriate outcomes. Editorials, letters to the editor, review articles, case reports and animal experimental studies were also excluded.

Data extraction and quality assessment {#sec009}
--------------------------------------

Studies were screened by two reviewers (R.W. and Y.W.) independently, and any disagreement was settled by consensus. First, the title and abstract of each study was read carefully to exclude the studies that clearly did not meet the inclusion criteria. Then, the full text of the remaining studies was read to determine which studies would be included in this study.

The quality assessment of RCTs was compiled using Cochrane's risk of bias tool \[[@pone.0175985.ref013]\], which included sequence generation, allocation concealment blinding of participants, personnel and outcome assessors, incomplete outcome data, selective outcome reporting, and other sources of bias.

Outcome measures {#sec010}
----------------

The main efficacy outcome measures included the clinical pregnancy rate (defined as the presence of a gestational sac on ultrasound or gestational sac with fetal heart tones), the ongoing pregnancy rate (determined as pregnancies with over 12 weeks of gestation), and the live birth rate. The secondary efficacy outcome measures were ovarian stimulation outcomes, which included stimulation days, gonadotropin dosage, endometrial thickness and estradiol (E2) level on the day of human chorionic gonadotrophin (HCG) administration, the number of oocytes retrieved, and the embryos obtained. The safety outcome measures included the incidence of OHSS, the miscarriage rate, and the cycle cancellation rate.

Statistical analysis {#sec011}
--------------------

All statistical analyses were performed using Revman 5.3 software. Dichotomous outcomes were expressed as odds ratios (ORs) with 95% confidence intervals (CIs). Continuous variables were expressed as weighted mean differences (MDs) with 95% CIs. Heterogeneity was evaluated using the Q-test and I^2^-index values, and reported for each outcome as a P-value and percentage, respectively. If heterogeneity was adopted (I^2^\<25% or \>50% with P\>0.1), meta-analysis used a fixed-effects model. Otherwise (I^2^≥50% or I^2^\>25% with P≤0.1), meta-analysis used a random-effects model. Sensitivity analysis was used to determine the stability of the results. Begg's funnel plot and Begg's test were used to assess publication bias by STATA software (version 12.0, Stata Corp).

Results {#sec012}
=======

Eligible studies {#sec013}
----------------

The initial literature search yielded 1,304 studies. Screening of the titles and abstracts resulted in 68 published articles that could possibly compare the GnRH-a long protocol and GnRH-ant protocol in patients with normal ovarian reserve. There is no official definition of normal ovarian reserve. Therefore, the studies included in our article mainly depended on a consensus, which met any two of the following criteria: Age \< 40 years, normal menstrual cycle, basal FSH ≤ 10 IU/L, basal E2 \< 60 pg/ml, AFC \> 5, previous IVF attempts \< 3, no previous poor response/OHSS history, no polycystic ovary syndrome (PCOS) / severe endometriosis. After reading the full papers, only 29 studies (6399 patients) finally met our inclusion criteria \[[@pone.0175985.ref008], [@pone.0175985.ref014]--[@pone.0175985.ref041]\]. Although the cited studies used different drugs and doses for COH, they all belong to either GnRH-ant protocol or GnRH-a protocol, so we included these studies in a general way. The literature screening process and the results are shown in [Fig 1](#pone.0175985.g001){ref-type="fig"}, and the basic characteristics of the included papers are shown in [Table 1](#pone.0175985.t001){ref-type="table"}. The quality assessment results are shown in [S1 Table](#pone.0175985.s001){ref-type="supplementary-material"}.

![Literature screening flow diagram.\
*From*: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). *P*referred *R*eporting *I*tems for *S*ystemetic Reviews and *M*eta-*A*nalyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:[10.1371/journal.pmed1000097](https://doi.org/10.1371/journal.pmed1000097).**For more information, visit [www.prisma-statement.org](http://www.prisma-statement.org)**.](pone.0175985.g001){#pone.0175985.g001}
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###### Characteristics of included studies.

![](pone.0175985.t001){#pone.0175985.t001g}

  Study                                          Inclusion Criteria                                                                                                                                                 No. of patients   Protocol   Gn type & initial dosage(IU/d)                                              
  ---------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------- ---------- --------------------------------------- ----------------------------------- ----------------------------
  Albano et al. 2000                             Age ≤39 y, basal FSH ≤10IU/L, regular menstrual cycle, previous IVF cycle ≤3                                                                                       198               95         Multiple dose (cetrorelix)              Long, multiple dose (buserelin)     HMG 150
  European Orgalutran. 2000                      Age ≤39 y, BMI 18--29 kg/m^2^, regular menstrual cycle                                                                                                             486               244        Multiple dose (ganirelix)               Long, multiple dose (buserelin)     rFSH 150
  Olivennes et al. 2000                          Age ≤39 y, basal FSH≤10IU/L, normal menstrual cycle, previous IVF attempts≤3                                                                                       126               43         Single dose (cetrorelix)                Long, single dose (triptorelin)     HMG unclear
  European and Middle East Orgalutration. 2001   Age \<39 y, BMI 18--29 kg/m^2^, regular menstrual cycle                                                                                                            236               119        Multiple dose (ganirelix)               Long, single dose (triptorelin)     rFSH 150
  Fluker et al. 2001                             Age \<39 y, basal FSH \<10 IU/L, basal LH \<10 IU/L, BMI 18--29 kg/m^2^, regular menstrual cycle                                                                   205               108        Multiple dose (ganirelix)               Long, multiple dose (leuprolide)    rFSH 225
  Hohmann et al.2003                             Age \<39 y, BMI 19--29 kg/m^2^, regular menstrual cycle, previous IVF attempts ≤3, no previous poor response/OHSS history                                          97                45         Multiple dose (cetrorelix)              Long, single dose (triptorelin)     rFSH 150
  Check et al. 2004                              Unclear                                                                                                                                                            30                30         Multiple dose (ganirelix)               Long, multiple dose (leuprolide)    rFSH300 or rFSH150+ HMG150
  Loutradis et al. 2004                          Age \<39 y, regular menstrual cycle, no previous poor response history                                                                                             58                58         Multiple dose (cetrorelix)              Long, multiple dose (triptorelin)   rFSH 225
  Sauer et al. 2004                              Age ≤39 y, BMI \<35 kg/m^2^, regular menstrual cycle, FSH level in normal range                                                                                    25                25         Single dose (cetrorelix)                Long, multiple dose (leuprolide)    rFSH 225
  Badrawi et al. 2005                            Age ≤39 y, basal FSH \<10 IU/L, regular menstrual cycle                                                                                                            50                50         Multiple dose (ganirelix)               Long, multiple dose (buserelin)     HMG 225
  Barmat et al. 2005                             Age \<39 y,BMI 19--32 kg/m^2^, basal FSH≤10 IU/L, E2\<60 pg/ml, AFC \>5, regular menstrual cycle, previous failed IVF cycle≤1, no previous poor response history   40                40         Multiple dose (ganirelix)               Long, multiple dose (leuprolide)    rFSH300
  Lee et al. 2005                                Age ≤39 y, BMI 18--29 kg/m^2^, basal FSH ≤10 IU/L, regular menstrual cycle, no previous poor response history                                                      20                20         Multiple dose (cetrorelix)              Long, multiple dose (buserelin)     HMG 225
  Xavier et al. 2005                             Age ≤39 y, basal FSH ≤10 IU/L, previous IVF attempts ≤3                                                                                                            66                65         Multiple dose (cetrorelix)              Long, multiple dose (buserelin)     rFSH 150--450
  Ferrari et al. 2006                            Age ≤39 y, BMI 20--25 kg/m^2^, basal FSH\< 10 IU/L, basal E2≤45 IU/L, regular menstrual cycle                                                                      30                30         Multiple dose (cetrorelix)              Long, multiple dose (leuprolide)    rFSH 225
  Friedler et al. 2006                           Age \<35 y, basal FSH≤10 IU/L                                                                                                                                      37                36         Multiple dose (ganirelix)               Long, multiple dose (buserelin)     rFSH 225
  Rombauts et al. 2006                           Age ≤39 y, BMI 18--29 kg/m^2^, normal menstrual cycle, previous failed IVF cycle ≤3, no previous poor response history                                             234               117        Multiple dose (ganirelix)               Long, multiple dose (nafarelin)     rFSH 200
  Serafini et al. 2006                           Age ≤39 y, basal FSH≤15 IU/L, basal E2≤60 IU/L, previous IVF attempts \<3, no previous poor response history                                                       217               106        Multiple dose (cetrorelix)              Long, multiple dose (leuprolide)    rFSH 150--300
  Baart et al. 2007                              Age \<38 y, BMI 19--29 kg/m^2^, regular menstrual cycle, no previous IVF attempt                                                                                   67                44         Multiple dose (orgalutran)              Long, multiple dose (triptorelin)   rFSH 150/225
  Heijnen et al. 2007                            Age \<38 y, BMI 18--28 kg/m^2^, regular menstrual cycle, no previous IVF attempt                                                                                   205               199        Unclear                                 Long, unclear                       Unclear
  Hsieh et al. 2008                              Age ≤39 y, body weight of 40--70 kg                                                                                                                                86                58         Multiple dose (cetrorelix)              Long, multiple dose (leuprolide)    rFSH 150--225
  Moraloglu et al. 2008                          Age ≤38 y, BMI \<30 kg/m^2^, basal FSH \<10 IU/L, previous IVF attempts ≤3, no previous poor response history, no PCOS                                             45                48         Multiple dose (cetrorelix)              Long, multiple dose (leuprolide)    rFSH 225
  Depalo et al. 2009                             Age≤42 y, basal FSH \<10 IU/L, previous IVF attempts≤3, no PCOS/ severe endometriosis                                                                              67                69         Multiple dose (cetrorelix)              Long, multiple dose (leuprolide)    rFSH 225
  Ye et al. 2009                                 Age ≤35 y, BMI 18--25 kg/m^2^, previous IVF attempts \<3, no previous poor response history, normal-ovulatory cycles                                               109               111        Multiple dose (cetrorelix)              Long, multiple dose (leuprolide)    rFSH 225
  Firouzabadi et al. 2010                        Age \<35 y, basal FSH \<10 IU/L, no previous IVF attempt                                                                                                           118               107        Multiple dose (ganirelix)               Long, multiple dose (buserelin)     rFSH 150--225
  Papanikolaou et al. 2012                       Age \<39 y, basal FSH \<12 IU/L, previous IVF attempts \<3,                                                                                                        96                94         Multiple dose (ganirelix/ cetrorelix)   Long, multiple dose (buserelin)     rFSH 150--300
  Qiao et al. 2012                               Age ≤35 y, BMI 18--29 kg/m^2^, normal menstrual cycle                                                                                                              113               120        Multiple dose (ganirelix)               Long, multiple dose (triptorelin)   rFSH unclear
  Rabati et al. 2012                             basal FSH ≤10 IU/L, first time of ART                                                                                                                              69                67         Multiple dose (cetrorelix)              Long, multiple dose (buserelin)     rFSH 75
  Hershko et al. 2015                            Age \<37 y, previous failed IVF cycles≤3, without ovulatory factor(WHO I-III)                                                                                      31                29         Multiple dose (cetrorelix)              Long, multiple dose (triptorelin)   rFSH /HMG
  Toftager et al. 2016                           Age \<40 y, previous IVF attempts \<3                                                                                                                              534               516        Multiple dose (ganirelix)               Long, multiple dose (nafarelin)     rFSH 150/225

Main outcome measures of effectiveness {#sec014}
--------------------------------------

### The clinical pregnancy rate {#sec015}

A total of 25 studies \[[@pone.0175985.ref008], [@pone.0175985.ref014]--[@pone.0175985.ref023], [@pone.0175985.ref025]--[@pone.0175985.ref029], [@pone.0175985.ref032]--[@pone.0175985.ref039], [@pone.0175985.ref041]\](5,814 cases) were included in the clinical pregnancy rate meta-analysis. There was no heterogeneity (P = 0.91, I^2^ = 0%) among the trials; therefore, the fixed-effects model was used for the meta-analysis. The results indicated that there was no statistically significant difference in the clinical pregnancy rate between the GnRH-ant group and the GnRH-a long-protocol group (OR \[95% CI\] = 0.90 \[0.80, 1.01\], P = 0.08, [Fig 2](#pone.0175985.g002){ref-type="fig"}).

![Forest plot comparing the clinical pregnancy rate per woman randomized between the GnRH-ant group and the GnRH-a long-protocol group.](pone.0175985.g002){#pone.0175985.g002}

### The ongoing pregnancy rate {#sec016}

A total of 18 studies \[[@pone.0175985.ref008], [@pone.0175985.ref014]--[@pone.0175985.ref020], [@pone.0175985.ref023], [@pone.0175985.ref028], [@pone.0175985.ref030], [@pone.0175985.ref031], [@pone.0175985.ref034], [@pone.0175985.ref036]--[@pone.0175985.ref039], [@pone.0175985.ref041]\](5,119 cases) were included in the ongoing pregnancy rate meta-analysis. There was no heterogeneity (P = 0.96, I^2^ = 0%) among the trials; therefore, the fixed-effects model was used for the meta-analysis. The results indicated that there was no statistically significant difference in the ongoing pregnancy rate between the GnRH-ant group and the GnRH-a long-protocol group (OR \[95% CI\] = 0.88 \[0.77, 1.00\], P = 0.05, [Fig 3](#pone.0175985.g003){ref-type="fig"}).

![Forest plot comparing the ongoing pregnancy rate per woman randomized between the GnRH-ant group and the GnRH-a long-protocol group.](pone.0175985.g003){#pone.0175985.g003}

### The live birth rate {#sec017}

A total of 6 studies \[[@pone.0175985.ref008], [@pone.0175985.ref014], [@pone.0175985.ref031], [@pone.0175985.ref035], [@pone.0175985.ref037], [@pone.0175985.ref041]\](2,237 cases) were included in the live birth rate meta-analysis. There was no heterogeneity (P = 0.88, I^2^ = 0%) among the trials; therefore, the fixed-effects model was used for the meta-analysis. The results indicated that there was no statistically significant difference in the live birth rate between the GnRH-ant group and the GnRH-a long-protocol group (OR \[95% CI\] = 0.95 \[0.74, 1.09\], P = 0.27, [Fig 4](#pone.0175985.g004){ref-type="fig"}).

![Forest plot comparing the live birth rate per woman randomized between the GnRH-ant group and the GnRH-a long-protocol group.](pone.0175985.g004){#pone.0175985.g004}

Secondary outcome measures of effectiveness {#sec018}
-------------------------------------------

### The number of stimulation days {#sec019}

A total of 17 studies \[[@pone.0175985.ref008], [@pone.0175985.ref014], [@pone.0175985.ref016], [@pone.0175985.ref021]--[@pone.0175985.ref027], [@pone.0175985.ref031], [@pone.0175985.ref033]--[@pone.0175985.ref035], [@pone.0175985.ref039]--[@pone.0175985.ref041]\](3,171 cases) were included in the number of stimulation days meta-analysis. There was heterogeneity (P\<0.00001, I^2^ = 96%) among the trials; therefore, the random-effects model was used for the meta-analysis. The results indicated that the stimulation days were statistically significantly fewer in the GnRH-ant group than in the GnRH-a long-protocol group (MD \[95% CI\] = -0.8 \[-1.36, -0.23\], P = 0.006, [Fig 5](#pone.0175985.g005){ref-type="fig"}).

![Forest plot comparing the number of stimulation days per woman randomized between the GnRH-ant group and the GnRH-a long-protocol group.](pone.0175985.g005){#pone.0175985.g005}

### Gn dosage {#sec020}

A total of 18 studies \[[@pone.0175985.ref008], [@pone.0175985.ref014], [@pone.0175985.ref016], [@pone.0175985.ref021]--[@pone.0175985.ref027], [@pone.0175985.ref031]--[@pone.0175985.ref036], [@pone.0175985.ref040], [@pone.0175985.ref041]\](3,424 cases) were included in the Gn dosage meta-analysis. There was heterogeneity (P\<0.00001, I^2^ = 94%) among the trials; therefore, the random-effects model was used for the meta-analysis. The results indicated that the Gn dosage was statistically significantly less in the GnRH-ant group than in the GnRH-a long-protocol group (MD \[95% CI\] = -3.52 \[-5.56, -1.48\], P = 0.0007, [Fig 6](#pone.0175985.g006){ref-type="fig"}).

![Forest plot comparing the Gn dosage per woman randomized between the GnRH-ant group and the GnRH-a long-protocol group.](pone.0175985.g006){#pone.0175985.g006}

### The endometrial thickness on the day of HCG administration {#sec021}

A total of 6 studies \[[@pone.0175985.ref023], [@pone.0175985.ref024], [@pone.0175985.ref027], [@pone.0175985.ref035], [@pone.0175985.ref036], [@pone.0175985.ref040]\](698 cases) were included in the meta-analysis of endometrial thickness on the day of HCG administration. There was no heterogeneity (P = 0.68, I^2^ = 0%) among the trials; therefore, the fixed-effects model was used for the meta-analysis. The results indicated that there was no statistically significant difference in the endometrial thickness on the day of HCG administration between the GnRH-ant group and the GnRH-a long-protocol group (MD \[95% CI\] = -0.06 \[-0.22, 0.11\], P = 0.5, [Fig 7](#pone.0175985.g007){ref-type="fig"}).

![Forest plot comparing the endometrial thickness on the day of HCG administration per woman randomized between the GnRH-ant group and the GnRH-a long-protocol group.](pone.0175985.g007){#pone.0175985.g007}

### The E2 level on the day of HCG administration {#sec022}

A total of 15 studies \[[@pone.0175985.ref008], [@pone.0175985.ref014], [@pone.0175985.ref016], [@pone.0175985.ref022]--[@pone.0175985.ref027], [@pone.0175985.ref032]--[@pone.0175985.ref034], [@pone.0175985.ref036], [@pone.0175985.ref039], [@pone.0175985.ref040]\](1,770 cases) were included in the E2 level on the day of HCG administration meta-analysis. There was heterogeneity (P\<0.00001, I^2^ = 91%) among the trials; therefore, the random-effects model was used for the meta-analysis. The results indicated that the E2 level on the day of HCG administration was statistically significantly lower in the GnRH-ant group than in the GnRH-a long-protocol group (MD \[95% CI\] = -365.49 \[-532.93, -198.05\], P\<0.0001, [Fig 8](#pone.0175985.g008){ref-type="fig"}).

![Forest plot comparing the E2 level on the day of HCG administration per woman randomized between the GnRH-ant group and the GnRH-a long-protocol group.](pone.0175985.g008){#pone.0175985.g008}

### The number of oocytes retrieved {#sec023}

A total of 22 studies \[[@pone.0175985.ref014]--[@pone.0175985.ref017], [@pone.0175985.ref020], [@pone.0175985.ref021], [@pone.0175985.ref023]--[@pone.0175985.ref027], [@pone.0175985.ref030]--[@pone.0175985.ref036], [@pone.0175985.ref038]--[@pone.0175985.ref041]\](4,919 cases) were included in the meta-analysis of the number of oocytes retrieved. There was heterogeneity (P = 0.01, I^2^ = 45%) among the trials; therefore, the random-effects model was used for the meta-analysis. The results indicated that the retrieved oocytes were statistically significantly fewer in the GnRH-ant group than in the GnRH-a long-protocol group (MD \[95% CI\] = -1.41 \[-1.84, -0.99\], P\<0.00001, [Fig 9](#pone.0175985.g009){ref-type="fig"}).

![Forest plot comparing the number of oocytes retrieved per woman randomized between the GnRH-ant group and the GnRH-a long-protocol group.](pone.0175985.g009){#pone.0175985.g009}

### The number of embryos obtained {#sec024}

A total of 11 studies \[[@pone.0175985.ref016], [@pone.0175985.ref017], [@pone.0175985.ref022]--[@pone.0175985.ref024], [@pone.0175985.ref027], [@pone.0175985.ref030], [@pone.0175985.ref032], [@pone.0175985.ref033], [@pone.0175985.ref035], [@pone.0175985.ref038]\](1,588 cases) were included in the meta-analysis of the number of embryos obtained. There was no heterogeneity (P = 0.68, I^2^ = 0%) among the trials; therefore, the fixed-effects model was used for the meta-analysis. The results indicated that the obtained embryos were statistically significantly fewer in the GnRH-ant group than in the GnRH-a long-protocol group (MD \[95% CI\] = -0.99 \[-1.38, -0.59\], P\<0.00001, [Fig 10](#pone.0175985.g010){ref-type="fig"}).

![Forest plot comparing the number of embryos obtained per woman randomized between the GnRH-ant group and the GnRH-a long-protocol group.](pone.0175985.g010){#pone.0175985.g010}

Outcome measures of safety {#sec025}
--------------------------

### The incidence of OHSS {#sec026}

A total of 21 studies \[[@pone.0175985.ref008], [@pone.0175985.ref014]--[@pone.0175985.ref019], [@pone.0175985.ref023]--[@pone.0175985.ref025], [@pone.0175985.ref028], [@pone.0175985.ref029], [@pone.0175985.ref031]--[@pone.0175985.ref033], [@pone.0175985.ref035]--[@pone.0175985.ref039], [@pone.0175985.ref041]\](5,763 cases) were included in the incidence of OHSS meta-analysis. There was no heterogeneity (P = 0.27, I^2^ = 15%) among the trials; therefore, the fixed-effects model was used for the meta-analysis. The results indicated that the incidence of OHSS was statistically significantly lower in the GnRH-ant group than in the GnRH-a long-protocol group (OR \[95% CI\] = 0.69 \[0.57, 0.83\], P\<0.0001, [Fig 11](#pone.0175985.g011){ref-type="fig"}).

![Forest plot comparing the incidence of OHSS per woman randomized between the GnRH-ant group and the GnRH-a long-protocol group.](pone.0175985.g011){#pone.0175985.g011}

### The miscarriage rate {#sec027}

A total of 14 studies \[[@pone.0175985.ref008], [@pone.0175985.ref014]--[@pone.0175985.ref020], [@pone.0175985.ref023], [@pone.0175985.ref032], [@pone.0175985.ref034]--[@pone.0175985.ref037]\](3,198 cases) were included in the miscarriage rate meta-analysis. There was no heterogeneity (P = 0.94, I^2^ = 0%) among the trials; therefore, the fixed-effects model was used for the meta-analysis. The results indicated that there was no statistically significant difference in the miscarriage rate between the GnRH-ant group and the GnRH-a long-protocol group (OR \[95% CI\] = 0.98 \[0.69, 1.40\], P = 0.93, [Fig 12](#pone.0175985.g012){ref-type="fig"}).

![Forest plot comparing the miscarriage rate per woman randomized between the GnRH-ant group and the GnRH-a long-protocol group.](pone.0175985.g012){#pone.0175985.g012}

### The cycle cancellation rate {#sec028}

A total of 19 studies \[[@pone.0175985.ref008], [@pone.0175985.ref014]--[@pone.0175985.ref020], [@pone.0175985.ref023], [@pone.0175985.ref025], [@pone.0175985.ref029]--[@pone.0175985.ref031], [@pone.0175985.ref033]--[@pone.0175985.ref036], [@pone.0175985.ref038], [@pone.0175985.ref041]\](5,209 cases) were included in the cycle cancellation rate meta-analysis. There was heterogeneity (P = 0.004, I^2^ = 53%) among the trials; therefore, the random-effects model was used for the meta-analysis. The results indicated that there was no statistically significant difference in the cycle cancellation rate between the GnRH-ant group and the GnRH-a long-protocol group (OR \[95% CI\] = 0.86 \[0.52, 1.44\], P = 0.57, [Fig 13](#pone.0175985.g013){ref-type="fig"}).

![Forest plot comparing the cycle cancellation rate per woman randomized between the GnRH-ant group and the GnRH-a long-protocol group.](pone.0175985.g013){#pone.0175985.g013}

Sensitivity analysis and publication bias {#sec029}
-----------------------------------------

The sensitivity analysis was performed by excluding the maximum weight studies \[[@pone.0175985.ref008], [@pone.0175985.ref017], [@pone.0175985.ref031], [@pone.0175985.ref036], [@pone.0175985.ref037], [@pone.0175985.ref041]\] in each outcome. The results showed that there was no influence on the pooled OR value; therefore, the outcomes are stable.

Begg's funnel plots were symmetrical, and Begg's tests had no significant publication bias (Begg's test P\>0.05, [S1](#pone.0175985.s003){ref-type="supplementary-material"}--[S12](#pone.0175985.s014){ref-type="supplementary-material"} Figs).

Discussion {#sec030}
==========

Summary of main results {#sec031}
-----------------------

Ovarian reserve can be tested by biochemical measures, such as basal follicle stimulating hormone (bFSH), anti-Mullerian hormone (AMH), and inhibin B level, as well as imaging measures, such as antral follicle count (AFC). The role of testing ovarian reserve is to help clinicians determine the appropriate protocol for individual patients, because ovarian reserve is the foundation of ovarian response to COH which may be vital for assisted reproductive technology (ART) outcome. Ovarian response can be divided into three types, low response, normal response, and high response. In 2011, the European Society of Human Reproduction and Embryology (ESHRE) standardized the definition of poor ovarian response \[[@pone.0175985.ref042]\], which usually occurs due to diminished ovarian reserve (DOR), and high response, which mainly refers to PCOS. However, there is no standard definition of normal ovarian reserve or normal response. Therefore, patients with normal ovarian reserve are included in our study to a certain extent based on a consensus.

Results of our meta-analysis mainly focused on the effectiveness and safety of GnRH antagonist protocol and GnRH agonist long protocol in COH. Regarding effectiveness, stimulation days, Gn dosage, E2 level on the day of HCG administration, and the number of oocytes retrieved, the embryos obtained were statistically significantly lower in GnRH-ant protocol than GnRH-a long protocol. The shorter stimulation period and lower Gn dosage in the GnRH-ant group may lead to the lower E2 level on the day of HCG administration, fewer retrieved oocytes, and fewer obtained embryos. However, regarding the main outcome measures of effectiveness, clinical pregnancy rate, ongoing pregnancy rate, and live birth rate had no significant differences between the two groups. The endometrial thickness on the day of HCG administration also showed no significant difference. This indicated that GnRH-ant protocol did not lead to a thicker endometrium on the day of HCG administration, and there was no difference in the reproductive outcome between the two groups. This means that even if the GnRH-ant protocol leads to fewer retrieved oocytes and fewer obtained embryos, this protocol does not reduce the chance of achieving a live birth. Moreover, GnRH-ant reduced the stimulation period and the Gn dosage, which is more convenient and cost-effective for patients.

The incidence of OHSS was statistically significantly lower in GnRH-ant protocol than in GnRH-a long protocol. This may because GnRH-ant protocol resulted in fewer retrieved oocytes, and a lower E2 level on the day of HCG administration, which had less possibility to induce OHSS than GnRH-a long protocol. No significant difference was found between the miscarriage rate, and the cycle cancellation rate between the two groups. Therefore, GnRH-ant protocol is safer because of the lower occurrence of OHSS without leading to miscarriage or cycle cancellation.

According to our results, GnRH-ant protocol can reduce the incidence of OHSS, faster and more cost-effectively, without affecting the reproductive outcome in normal ovarian reserve patients. Therefore, GnRH-ant protocol should be used as widely as GnRH-a protocol in these patients.

Comparison with other studies {#sec032}
-----------------------------

The recent Cochrane systematic review of 73 RCTs in 2016 has concluded that GnRH-ant protocol and GnRH-a protocol have equivalent live birth rates, while GnRH-ant protocol has a lower incidence of OHSS \[[@pone.0175985.ref011]\]. Their results are similar to ours. However, the patients with all types of ovarian reserve were included in their study, which covered DOR and PCOS.

A meta-analysis focusing on the supposed normal ovarian responders, including 23 RCTs (n = 3961), was conducted in 2014 \[[@pone.0175985.ref043]\]. The results indicated that the incidence of OHSS was significantly lower, whereas the ongoing pregnancy and live birth rates were similar in the GnRH antagonist and the standard long GnRH agonist protocols, which is similar to the results of our meta-analysis.

Another systematic review and meta-analysis of 22 RCTs (n = 3176) comparing GnRH-ant and GnRH-a reported the live birth as their main outcome measure \[[@pone.0175985.ref007]\]. No significant difference was present in the probability of live birth between the two GnRH analogs \[OR = 0.86; 95% CI = 0.72 to 1.02\]. This result remains stable in subgroup analysis that ordered the studies by type of population studied, Gn type used for stimulation, type of agonist protocol used, type of agonist used, type of antagonist protocol used, type of antagonist used, presence of allocation concealment, presence of co-intervention, and the way the information on live birth was retrieved. However, their study also included all types of ovarian reserve.

Additionally, a meta-analysis of four RCTs (n = 874) in 2008 mainly measured ongoing pregnancy rate \[[@pone.0175985.ref044]\]. The ongoing pregnancy rate per randomized woman was not found to be significantly different between patients with and without oral contraceptive pill (OCP) pretreatment (OR: 0.74, 95% CI: 0.53 to 1.03). Duration of Gn stimulation (WMD: 1.41 days, 95% CI: 1.13 to 1.68) and Gn consumption (WMD: 542 IU, 95% CI: 127 to 956) were significantly increased after OCP pretreatment. No significant differences were observed regarding the number of retrieved oocytes. However, the patients included in their study were also not classified by ovarian reserve.

Limitations of this study {#sec033}
-------------------------

First of all, this meta-analysis lacked a uniform definition of normal ovarian reserve, which made it difficult to define inclusion and exclusion criteria, and the studies included may be not strict enough. Second, although the random-effects model was used to minimize the heterogeneity, it cannot be abolished. The heterogeneity may relate to the size of studies that ranged from 40 to 1,050 patients, and to the time span between 2000 and 2016. Additionally, the quality of reported studies was uneven, which may also lead to heterogeneity. The methods of randomization, concealment, and blinding were unclear in some included studies, some of which also had incomplete and selective outcome data. Third, although comprehensive searches were undertaken to ensure that all eligible studies were included, there is still the possibility that some potentially eligible studies were left out. All of these factors may lead to bias.

Implications {#sec034}
------------

The GnRH-ant protocol is a short, convenient, and cost-effective protocol in COH among patients with normal ovarian reserve, which can also reduce the incidence of OHSS without affecting the live birth rate when compared to GnRH-a long protocol. When referring to patients with normal ovarian reserve, in future clinical practice, GnRH-ant protocol may also be a good choice for COH. Moreover, a uniform definition for ovarian reserve, especially for normal ovarian reserve, should be standardized as soon as possible. RCTs of GnRH-ant protocol and GnRH-a long protocol in patients with different ovarian reserve are still lacking. And the study design of future RCTs should be more rigorous according to the CONSORT statement \[[@pone.0175985.ref045]\].

Conclusion {#sec035}
==========

In conclusion, our meta-analysis demonstrated that GnRH antagonist protocol substantially decreased the incidence of OHSS without influencing the pregnancy rate and live birth rate compared to GnRH agonist long protocol among patients with normal ovarian reserve. Therefore, for patients with normal ovarian reserve, GnRH-ant protocol should play a more important role in COH when clinicians are making individualizing and optimizing treatment decisions.
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